A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture
NCT ID: NCT01845623
Last Updated: 2017-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2013-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device
NCT01484197
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
NCT01959412
Efficacy and Safety of Different Doses of Indacaterol
NCT01079130
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
NCT00556673
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
NCT03257995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A
QAB149 75 mg Concept 1
QAB149 delivered via the concept 1 device.
Placebo EPIC Test Fixture
Placebo administered via the EPIC Test Fixture.
Treatment B
QAB149 75 mg Epic Test Fixture
QAB149 delivered via the EPIC test fixture
Placebo Concept 1
Placebo administered via the Concept 1 device.
Treatment C
Placebo Concept 1
Placebo administered via the Concept 1 device.
Placebo EPIC Test Fixture
Placebo administered via the EPIC Test Fixture.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QAB149 75 mg Concept 1
QAB149 delivered via the concept 1 device.
QAB149 75 mg Epic Test Fixture
QAB149 delivered via the EPIC test fixture
Placebo Concept 1
Placebo administered via the Concept 1 device.
Placebo EPIC Test Fixture
Placebo administered via the EPIC Test Fixture.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-001824-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CMID001A2201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.